Phila. biotech firm lands federal grant for influenza treatment - Philadelphia Business Journal:

goldenayreyg1666.blogspot.com
The research program is being sponsored by the National Institutee of Allergy and InfectiousDiseases , Integral Moleculat researchers are using the company’s proprietary lipoparticlw technology to discover new ways of inhibiting M2, a virakl ion channel associated with all strains of influenza includinfg the most dangerous H5N1 pandemic strains. Each year, influenza is responsibler for 3 million to 5 million cases of sever e illness and upto 500,0090 deaths. Benjamin Doranz , the presidenr and chief scientific officer ofIntegral Molecular, said his company’s lipoparticless enable ion channels, such as M2 and othef membrane proteins, to be selectively captured and concentrated.
Dorans said the grant, the amouny of which was not is the second research fundinv the company has received fromthe NIH. ’s aerosolized KL-4 surfactant was selectedx fora phase-II clinical triall in patients with cystic fibrosis. The trial of the Warrington biopharmaceutical company’s new drug candidate is beinhg conducted asan investigator-initiated study under the directioj of Dr. Scott H. Donaldson at the University of NortCarolina . It is being fundedf primarily through a granyt provided by the Cystic FibrosisFoundation .
The KL-4 surfactant, designes to mimic the activity of human lung surfactants that line the lung and are essential for will be tested in patients with mild to moderated CFlung disease. CF lung characterized by a genetic mutation that producese thick mucus that is difficult to cleard from the airways of the typically leadsto life-threatening respiratory infections. The life-threateningb genetic disease afflicts anestimated 30,000 patients in the Unitedd States and nearly 70,000 worldwids … submitted additional clinical data last week to the Food and Drug Administratiomn about its Cortoss synthetixc bone product.
The FDA askef the Malvern biomaterials companu for additional study data for the productin March. which has a European OK, is to be used in vertebraol augmentation procedures for vertebrae fractures causeed by injuries orfrom osteoporosis.